Journal
EXPERT REVIEW OF VACCINES
Volume 11, Issue 6, Pages 733-744Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.12.35
Keywords
adjuvant; adjuvant mechanisms; adjuvant systems; data mining; lipid A; liposomes; monophosphoryl lipid A; patents and intellectual property; peptide vaccines
Categories
Funding
- Henry M Jackson Foundation for the Advancement of Military Medicine [W81XWH-07-2-067]
- US Army Medical Research and Materiel Command [W81XWH-07-2-067]
Ask authors/readers for more resources
Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available